ACA
KAPA

Aptus Capital Advisors’s Kairos Pharma KAPA Stock Holding History

Aptus Capital Advisors’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Hold
44,286
– – ﹤0.01% 1548
2026
Q1 		$24.8K Hold
44,286
– – ﹤0.01% 1373
2025
Q4 		$31.4K Hold
44,286
– – ﹤0.01% 1357
2025
Q3 		$51.8K Hold
44,286
– – ﹤0.01% 1224
2025
Q2 		$31.4K Hold
44,286
– – ﹤0.01% 1229
2025
Q1 		$41.5K Buy
+44,286
New +$56.7K ﹤0.01% 1134

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Aptus Capital Advisors's KAPA Position: Q2 2026 in Review

Aptus Capital Advisors held its Kairos Pharma (KAPA) position steady in Q2 2026 at 44,286 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1548.

Aptus Capital Advisors first reported a position in KAPA in Q1 2025 and has held it in 6 quarters since. The position peaked at $51.8K in Q3 2025. 9 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • Aptus Capital Advisors held 44,286 shares of Kairos Pharma worth $17K as of Q2 2026.
  • Aptus Capital Advisors left its Kairos Pharma share count unchanged in Q2 2026.
  • Kairos Pharma made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1548 holding.
  • Aptus Capital Advisors first reported a position in Kairos Pharma in Q1 2025 and has held it in 6 quarters since.
  • Aptus Capital Advisors's Kairos Pharma position peaked at $51.8K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.